Marion Subklewe
Marion Subklewe is an expert in Hematology at LMU Klinikum (Germany). As of October 2026, ScienceLeadR ranks Marion Subklewe in the top 1% of experts worldwide for Leukemia, Lymphoma and Lymphoproliferative Disorders. Marion Subklewe has authored 516 publications, the most recent in 2026, and is an investigator in 23 clinical trials, 8 of them ongoing. SLR score: 2,502 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1999 - 2026
Number : 516
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Organ-specific depth of response to CD19-directed CAR T-cell therapy in B-cell lymphomas. PMID 42931850 — cells, lymphoma, b-cell, lymphoma, neoplasms, immunotherapy, tumor burden, therapeutics, wounds and injuries, t-lymphocytes, b-lymphocytes, receptors, antigen, t-cell, car-t cell | Cancer Immunol Immunother | 2026 | 0 |
| Clinical Features and Outcomes of Therapy-Related Myeloid Neoplasms After CAR T-Cell Therapy. PMID 42842872 — cells, neoplasms, therapeutics, t-lymphocytes, car-t cell | Blood Adv | 2026 | 0 |
| A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist. PMID 42835773 — cells, leukemia, cell line, research, therapeutics | Hemasphere | 2026 | 0 |
| Pre-treatment T cell features and immune-milieu characteristics shape treatment-induced exhaustion and resistance to Blinatumomab in B-cell acute lymphoblastic leukemia. PMID 42694115 — cells, precursor cell lymphoblastic leukemia-lymphoma, leukemia, immune system diseases, therapeutics, t-lymphocytes, b-lymphocytes | Front Immunol | 2026 | 0 |
| Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study. PMID 42689432 — cells, hematology, safety, neutropenia, leukemia, recycling, leukemia, myeloid, acute, azacitidine, leukemia, myeloid, therapeutics | Haematologica | 2026 | 0 |
Clinical Studies 23
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
8 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A PHASE 1 OPEN LABEL DOSE ESCALATION AND DOSE EXPANSION STUDY OF CLN 049 FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) 2023-506572-27-00 — leukemia, leukemia, myeloid, acute, leukemia, myeloid, therapeutics | Phase 1 | Recruiting | 2024 |
| A trial to learn how safe AZD3632 is how well it works and how it moves throughout the body over time in adults with acute leukemia and myelodysplastic syndrome with HOX gene overexpression 2025-521299-76-00 — genes, myelodysplastic syndromes, safety, antineoplastic agents, multiple chronic conditions, leukemia, genotype, genes, homeobox, pharmacokinetics | Phase 1/Phase 2 | Recruiting | 2025 |
| Phase 1 Study of Allo RevCAR01 T CD123 in Patients With Selected CD123 Positive Hematologic Malignancies 2022-501797-19-00 — hematologic neoplasms | Phase 1 | Recruiting | 2023 |
| CAR T cell Treatment for Untreated High Risk MANtle Cell Lymphoma NCT06482684 — cells, lymphoma, maintenance, rituximab, lymphoma, mantle-cell, therapeutics, t-lymphocytes, car-t cell | Phase 2 | Recruiting | 2024 |
| An Adaptive Open label Multicentre Phase 1 2 Trial to Determine the Recommended Phase 2 Dose of CCTx 001 and to Assess Safety Tolerability and Clinical Activity in Patients With Relapsed Refractory Acute Myeloid Leukaemia NCT06281847 — cells, safety, suspensions, leukemia, leukemia, myeloid, acute, leukemia, myeloid, dimethyl sulfoxide, car-t cell | Phase 1/Phase 2 | Not yet recruiting | 2025 |
LeadR Networks
Main global connection map